Jing Liu

Jing Liu

Auto-generated profile, based on publicly available information

Jing Liu

Department of Physiology, College of Medicine – Tucson, University of Arizona, Tucson, Arizona

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
YCYuan Cheng
Yuan Cheng
DWDandan Wang
Dandan Wang
FWFeng Wang
Feng Wang
JLJing Liu
Jing Liu
BHBaorui Huang
Baorui Huang
MLMingyu Liang
Mingyu Liang
Significance Statement: Several microRNAs have been shown to play significant roles in the development of renal injury. The microRNA miR-204-5p is highly enriched in the kidney but its involvement in chronic renal injury is unknown. In this study, the authors report that miR-204-5p abundance is significantly decreased in kidney biopsy samples from patients with hypertension, hypertensive nephrosclerosis, or diabetic nephropathy. They also found, in a rat model of salt-sensitive hypertension, a mouse model of hypertension, and a mouse model of type 2 diabetes, inhibition of miR-204-5p, or deletion of the Mir204 gene results in upregulation of an injurious molecular pathway and substantial exacerbation of renal injury. These findings provide evidence of a prominent role for miR-204-5p in safeguarding the kidneys against common causes of chronic renal injury. Background: Aberrant microRNA (miRNA) expression affects biologic processes and downstream genes that are crucial to CKD initiation or progression. The miRNA miR-204-5p is highly expressed in the kidney but whether miR-204-5p plays any role in the development of chronic renal injury is unknown. Methods: We used real-time PCR to determine levels of miR-204 in human kidney biopsies and animal models. We generated Mir204 knockout mice and used locked nucleic acid–modified anti-miR to knock down miR-204-5p in mice and rats. We used a number of physiologic, histologic, and molecular techniques to analyze the potential role of miR-204-5p in three models of renal injury. Results: Kidneys of patients with hypertension, hypertensive nephrosclerosis, or diabetic nephropathy exhibited a significant decrease in miR-204-5p compared with controls. Dahl salt-sensitive rats displayed lower levels of renal miR-204-5p compared with partially protected congenic SS.13BN26 rats. Administering anti–miR-204-5p to SS.13BN26 rats exacerbated interlobular artery thickening and renal interstitial fibrosis. In a mouse model of hypertensive renal injury induced by uninephrectomy, angiotensin II, and a high-salt diet, Mir204 gene knockout significantly exacerbated albuminuria, renal interstitial fibrosis, and interlobular artery thickening, despite attenuation of hypertension. In diabetic db/db mice, administering anti–miR-204-5p exacerbated albuminuria and cortical fibrosis without influencing blood glucose levels. In all three models, inhibiting miR-204-5p or deleting Mir204 led to upregulation of protein tyrosine phosphatase SHP2, a target gene of miR-204-5p, and increased phosphorylation of signal transducer and activator of transcription 3, or STAT3, which is an injury-promoting effector of SHP2. Conclusions: These findings indicate that the highly expressed miR-204-5p plays a prominent role in safeguarding the kidneys against common causes of chronic renal injury.

13 January 2020
Verified
Journal Article
Closed access
JLJing Liu
Jing Liu
HSHisashi Sawada
Hisashi Sawada
DHDeborah A. Howatt
Deborah A. Howatt
JMJessica J. Moorleghen
Jessica J. Moorleghen
OVOlga Vsevolozhskaya
Olga Vsevolozhskaya
Hong S LuHong S Lu
Hong S Lu

3 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJing Liu
Jing Liu
Hisashi SawadaHisashi Sawada
Hisashi Sawada
DHDeborah A. Howatt
Deborah A. Howatt
JMJessica J. Moorleghen
Jessica J. Moorleghen
OVOlga Vsevolozhskaya
Olga Vsevolozhskaya
Hong S LuHong S Lu
Hong S Lu
Objective: This study determined whether hypercholesterolemia would contribute to both the initiation and progression of angiotensin (Ang)II-induced abdominal aortic aneurysms (AAAs) in mice. Methods and Results: To determine whether hypercholesterolemia accelerates the initiation of AAAs, male low-density lipoprotein (LDL) receptor -/- mice were either fed one week of Western diet prior to starting AngII infusion or initiated Western diet one week after starting AngII infusion. During the first week of AngII infusion, mice fed normal diet had less luminal expansion of the suprarenal aorta compared to those initiated Western diet after the first week of AngII infusion. The two groups achieved comparable luminal dilation on week 2 through week 6 of AngII infusion as monitored by ultrasound. To determine whether hypercholesterolemia contributed to the progression of established AAAs, male LDL receptor -/- mice were fed Western diet and infused with AngII for 4 weeks. Mice with established AAAs were then stratified into two groups based on luminal diameters measured by ultrasound. While AngII infusion was continued for another 8 weeks in both groups, mice in one group were continuously fed Western diet, but diet in the other group was switched to normal laboratory diet. In the latter group, plasma cholesterol concentrations were reduced rapidly to approximately 500 mg/dl within one week after the diet was switched from Western diet to normal laboratory diet. Luminal expansion progressed constantly in mice continuously fed Western diet, whereas no continuous expansion was detected in mice that were switched to normal laboratory diet. Conclusions: Hypercholesterolemia accelerates both the initiation of AAAs and progression of established AAAs in AngII-infused male LDL receptor -/- mice. Clinical Relevance: Hypercholesterolemia is modestly associated with AAAs in observational or retrospective clinical studies. It is not feasible to study whether hypercholesterolemia contributes to the initiation of AAAs or progression of established AAAs in human. This study using AngII-induced AAA mouse model provides solid evidence that hypercholesterolemia contributes to both the initiation and progression of AAAs, supporting that statin therapy at any stage of AAA development may be beneficial to hypercholesterolemic patients with AAAs.

13 August 2026 in Science
Verified
Journal Article
Closed access
QQQiongzi Qiu
Qiongzi Qiu
YLYong Liu
Yong Liu
HXHong Xue
Hong Xue
RPRajan Pandey
Rajan Pandey
JLJing Liu
Jing Liu
MLMingyu Liang
Mingyu Liang
Hypertension is a leading cause of disease burden and mortality. Here, we present a single-cell analysis of hypertension and end-organ damage across six organs and tissues in angiotensin II–treated mice, Dahl salt–sensitive rats, and spontaneously hypertensive rats. We identified gene programs associated with blood pressure and renal injury, including a conserved vascular smooth muscle cell program and cross-segment renal tubular programs, along with tissue-specialized endothelial adaptations and coordinated changes across cell types in select organs. Integration with human genomic data revealed model-specific and shared cell type–trait links. We prioritized a noncoding variant (rs28451064) and used genome editing to demonstrate its in vivo effect on blood pressure and allele-specific regulation of local genes. Our study provides a multimodel, cross-organ cellular resource for hypertension research.

21 September 2025 in bioRxiv
Verified
Preprint
Open access
JLJing Liu
Jing Liu
QQQiongzi Qiu
Qiongzi Qiu
CKChristine A. Klemens
Christine A. Klemens
VGVineetha Garimella
Vineetha Garimella
JHJing Huang
Jing Huang
JWJing O. Wu
Jing O. Wu
Per– and polyfluoroalkyl substances (PFAS) are synthetic chemicals found in the plasma of 98% of Americans. Epidemiological studies associate PFAS exposure with hypertension and kidney dysfunction, but causality and mechanisms remain unclear. We examined the effects of a mixture of 4 PFAS commonly detected in humans, including PFOA, PFOS, PFHxS, and PFNA, on blood pressure, salt sensitivity, and renal injury in 129S6 mice. Exposure to a lower dose for 3 weeks produced plasma PFAS levels in mice resembling occupational and regional environmental exposures; while a upper dose achieved levels similar to PFAS production workers. PFAS induced dose-dependent pressor effects in male but not female mice on a 0.4% low salt diet. During 4% high salt feeding, PFAS induced greater salt-sensitive hypertension in male mice, accompanied by glomerulopathy, interstitial fibrosis, and a trend towards increased albuminuria. Pressor effects were independent of plasma norepinephrine. Single-cell RNA sequencing of kidneys revealed most transcriptional changes in proximal tubule, thick ascending limb, and collecting duct, with enrichment of pathways in cholesterol synthesis, mitochondria respiration, ATP production, and transmembrane transporter activity. PFAS markedly increased the mRNA and protein of the pore-forming α subunit of epithelial sodium channel (αENaC), with no change in βENaC and a slight reduction in γENaC protein. Elevated αENaC coincided with a 30% decrease in Nedd4-2 phosphorylation (Ser448), suggesting reduced ENaC ubiquitination and degradation. However, protein expression of α1 Na + -K + -ATPase and serum– and glucocorticoid-regulated kinase 1 (SGK1) as well as SGK1 phosphorylation (Ser78) were unaltered. Amiloride abolished salt-induced hypertension in lower-dose mice but only partially corrected hypertension in the upper dose group. Taken together, our results provide causal evidence that PFAS exposure promotes hypertension, salt sensitivity, and kidney injury via renal epithelial mechanisms, supporting and extending human epidemiologic observations. Translational Statement: Our findings establish four PFAS as causal drivers of salt-sensitive hypertension and kidney injury through convergent effects on ENaC and other tubular sodium transporters. These results not only provide a mechanistic explanation for epidemiologic associations but also identify PFAS as environmental amplifiers of dietary sodium risk. Given the ubiquity of human exposure, reducing PFAS burden alongside salt reduction may represent a complementary strategy to curb the global epidemic of hypertension and kidney disease.

1 July 2025 in Kidney360
Verified
Journal Article
Open access
JLJing Liu
Jing Liu
FBFrank C. Brosius
Frank C. Brosius
JWJing O. Wu
Jing O. Wu